ATHE vs ICCC

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score limits bankruptcy risk assessment. Despite strong revenue growth of 80.90% YoY and a pristine balance sheet with zero debt and a current ratio of 12.98, the company is deeply unprofitable with a profit margin of -223.35% and negative ROE of -43.23%. Valuation metrics are extreme, with a Price/Book of 1038.03 and a negative Forward P/E of -4.49, suggesting significant overvaluation relative to book and earnings. While insider sentiment is moderately positive at 40/100 and analysts project a high target price of $12.00, the lack of profitability, inconsistent cash flow data, and weak technical trend (0/100) raise serious concerns about sustainability.

ImmuCell Corporation exhibits significant fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the company maintains a strong liquidity position with a current ratio of 4.26, this is offset by negative revenue growth (-1.60%) and a lack of profitability. Despite a recent short-term price rally, the long-term technical trend remains overwhelmingly bearish (10/100). The absence of analyst coverage and deterministic value metrics suggests a high-risk micro-cap profile with failing fundamental momentum.